Siemens Healthineers (OTCMKTS:SMMNY) Releases Earnings Results, Beats Expectations By $0.11 EPS

Posted by Brenda Bartman on Jul 31st, 2026

Siemens Healthineers (OTCMKTS:SMMNY – Get Free Report) announced its quarterly earnings results on Friday. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.30 by $0.11, Zacks reports.

Siemens Healthineers Stock Down 0.6%

Shares of SMMNY stock traded down $0.13 during trading on Friday, hitting $21.38. The company had a trading volume of 125,312 shares, compared to its average volume of 159,724. The stock’s 50-day moving average is $19.94 and its two-hundred day moving average is $21.82. Siemens Healthineers has a 52 week low of $19.20 and a 52 week high of $28.92.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut shares of Siemens Healthineers from a “hold” rating to a “strong sell” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Siemens Healthineers currently has a consensus rating of “Moderate Buy”.

Read Our Latest Analysis on SMMNY

About Siemens Healthineers

(Get Free Report)

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.